Company Overview
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products specifically within the Canadian market, offering a diverse portfolio that includes medical cannabis varieties such as whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates, alongside adult use recreational cannabis. The company operates within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which positions it as a key player in the pharmaceutical and therapeutic goods landscape focused on specialized therapeutic applications. With a market capitalization of $190.29M, annual revenue of $279.99M, and an employee count of 1137, the organization represents a mid-cap entity with a substantial operational footprint. These valuation and revenue figures indicate that Organigram Global Inc. has achieved significant scale in the competitive cannabis manufacturing space, maintaining a workforce large enough to support complex production and distribution networks while holding a market presence that reflects its established position in the sector.
Financial Health
The company reported revenue of $279.99M over the trailing twelve months, generating a net income of $18.17M and an EBITDA of $5.43M. The significant gap between the revenue figure of $279.99M and the net income of $18.17M reveals a cost structure where operating expenses and taxes consume a substantial portion of gross sales, leaving a profit margin of 6.5% despite a gross margin of 35.6%. The free cash flow stands at -$39,607,124, which indicates that the company is currently burning cash, suggesting limited financial flexibility for immediate large-scale expansions without external financing. Analyzing the three distinct margins shows that while the gross margin of 35.6% demonstrates strong pricing power or cost efficiency in production, the negative operating margin of -5.4% highlights high overhead costs or strategic investments that are depressing current profitability before interest and taxes. The company holds cash of $8.38M against total debt of $8.45M, resulting in a debt-to-equity ratio of 1.99, which suggests a leveraged balance sheet where debt obligations slightly exceed liquid cash reserves. The current ratio of 2.73 indicates a robust short-term liquidity position, as the company possesses more than double the current assets needed to cover its current liabilities. Return on Equity is 4.6% and Return on Assets is -1.5%, revealing that while equity holders are seeing a modest return, the company's asset base is currently generating negative returns, likely due to the heavy investment phase or operational inefficiencies reflected in the negative operating margin.
Valuation Assessment
The trailing twelve-month P/E ratio is 12.55, whereas the forward P/E ratio is significantly higher at 76.67, implying that the market expects a dramatic turnaround in earnings or that current earnings are exceptionally low relative to future expectations. The price-to-book ratio is 0.69, indicating that the market values the company at roughly 69% of its book value, which suggests the stock is trading at a discount to its net asset value. The price-to-sales ratio is 0.68 and the EV/EBITDA is 44.47, metrics that suggest the company is priced based on sales multiples rather than current earnings power, often seen in high-growth or turnaround situations where traditional P/E metrics are less reliable. The 52-week high is $2.24 and the 52-week low is $0.85, and without a specific current price provided in the facts, the valuation context relies on these historical bounds to establish the volatility range within which the stock has traded. The beta value is 1.93, which means the stock's price volatility is nearly double that of the broader market, indicating high sensitivity to market movements and increased risk for investors compared to lower beta peers.
Growth & Income
The revenue growth year-over-year is 48.7%, while earnings growth is marked as N/A, indicating that while top-line sales are expanding rapidly, the bottom line has not yet stabilized to a consistent growth trajectory. Since earnings growth is N/A and the company does not pay a dividend with a yield of N/A and a payout ratio of 0.0%, the company is effectively reinvesting all available earnings and cash flow back into the business to fuel revenue expansion rather than distributing income to shareholders. The absence of a dividend yield and the zero payout ratio confirm that Organigram Global Inc. is a growth-oriented entity that prioritizes capital allocation toward operational scaling over immediate income generation for investors. The overall growth and income profile is characterized by aggressive revenue expansion in the Canadian cannabis market supported by a zero-dividend strategy and a valuation that reflects high expectations for future earnings normalization.